Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients

Enrica Marchi, Lapo Alinari, Monica Tani, Vittorio Stefoni, Nicola Pimpinelli, Emilio Berti, Livio Pagano, Maria Grazia Bernengo, Francesco Zaja, Serena Rupoli, Stefano Pileri, Michele Baccarani, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL. METHODS. Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28-day schedule at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles. RESULTS. Of the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4-22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted. CONCLUSIONS. The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed.

Original languageEnglish
Pages (from-to)2437-2441
Number of pages5
JournalCancer
Volume104
Issue number11
DOIs
Publication statusPublished - Dec 1 2005

Keywords

  • Cutaneous T-cell lymphoma (CTCL)
  • Gemcitabine
  • Untreated patients

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients'. Together they form a unique fingerprint.

Cite this